# Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study

> **NCT03233178** · — · COMPLETED · sponsor: **LMC Diabetes & Endocrinology Ltd.** · enrollment: 4000 (actual)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)
- Fatty Liver
- NAFLD

## Interventions

- **OTHER:** Non-interventional

## Key facts

- **NCT ID:** NCT03233178
- **Lead sponsor:** LMC Diabetes & Endocrinology Ltd.
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01
- **Primary completion:** 2017-06
- **Final completion:** 2017-06
- **Target enrollment:** 4000 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03233178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03233178, "Measurement of Alanine Aminotransaminase (ALT) Following Initiation of Antidiabetic Agents in Patients With Type 2 Diabetes in a Real-world Clinical Setting: a Retrospective Cohort Study". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03233178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*